Santhera Pharmaceuticals Extends Agamree Distribution Agreement with Biomedica

01:21 AM EDT, 07/13/2026 (MT Newswires) -- Santhera Pharmaceuticals (SANN.SW) extended its exclusive distribution deal for its Duchenne muscular dystrophy drug, Agamree, with Biomedica to include five more countries. The expanded agreement covers Georgia, Kazakhstan, Belarus, Azerbaijan, and Uzbekistan, according to a Monday release. Biomedica was appointed as a distributor for Agamree in October 2025, while the Swiss specialty pharmaceutical company receives a certain percentage of the net sales.